How one family gave a critical boost to gene therapy research

A family affected by Sanfilippo syndrome raised millions of dollars for research. The Food and Drug Administration just approved a gene therapy the support helped make possible.

The top 3

  1. Bridging the 'Valley of Death' in Early Research: Academic research for rare diseases often faces abandonment due to lack of funding before human trials. Patient foundations acted as the critical capital provider for researcher Haiyan Fu, sustaining the project for years after it was slated for termination, eventually enabling the transition to biotech commercialization.
  2. Scaling Advocacy through Digital Engagement: The O'Neill family successfully utilized viral digital media to generate immediate, large-scale public donations, which directly funded the transition to the first human clinical trials. This model demonstrates how non-traditional fundraising can prove the market and scientific validity of a therapy to attract later-stage corporate partners like Ultragenyx.
  3. Clinical Efficacy and Treatment Timing: The therapeutic benefit of the gene therapy (Fayuvi) is highly dependent on early intervention. Because Sanfilippo syndrome causes irreversible neurological damage, patients treated at an older age see limited functional recovery, whereas younger infants have shown better outcomes.

Sources

Open the full topic